Market Cap (In GBp)
187.2 Million
Revenue (In GBp)
506 Thousand
Net Income (In GBp)
-7.66 Million
Avg. Volume
931.00
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 640.0-1820.0
- PE
- -
- EPS
- -
- Beta Value
- 1.126
- ISIN
- GB00BMCLYF79
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Heikki Lanckriet Ph.D.
- Employee Count
- -
- Website
- https://www.4basebio.com
- Ipo Date
- 2021-02-17
- Details
- 4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
More Stocks
-
EC
-
0QKBLEM Holding SA
0QKB
-
ECAOF
-
PANR
-
QRSQuercus TFI S.A.
QRS
-
XPL
-
MGX
-
QRC